Charles J. Dockendorff - 24 Jul 2025 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Reporting relationship: Director
Issuer ticker: HAE
Reported as of: 24 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Jul 2025, 16:25:51 UTC
Prior SEC filing: 25 Mar 2025
Next SEC filing: 02 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. Dockendorff

Filing notes and source

Key filing fact

Charles J. Dockendorff filed Form 4 for HAEMONETICS CORP (HAE) on 25 Jul 2025.

Key facts

This page summarizes Charles J. Dockendorff's Form 4 filing for HAEMONETICS CORP (HAE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Jul 2025, 16:25.

Change

Previous filing in this sequence was filed on 25 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001400563 Primary reporting owner

Dockendorff Charles J

Relationship: Director
Address: 125 SUMMER STREET, BOSTON
Signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. Dockendorff
Signature date: 25 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HAE transaction

Common Stock

Award

Transaction value
Shares: +2,693
Change %: +61%
Price
Shares after: 7,126
Date: 24 Jul 2025
Ownership: Direct
Footnotes: F1, F2

HAE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 17,915
Date: 24 Jul 2025
Ownership: Spouse?s Revocable Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Footnote F2

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.